Teriparatide + Alendronate Sodium + Placebo + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Osteoporosis
Conditions
Osteoporosis
Trial Timeline
Nov 1, 2002 → Jan 1, 2008
NCT ID
NCT00051558About Teriparatide + Alendronate Sodium + Placebo + Placebo
Teriparatide + Alendronate Sodium + Placebo + Placebo is a phase 3 stage product being developed by Eli Lilly for Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00051558. Target conditions include Osteoporosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00051558 | Phase 3 | Completed |
Competing Products
20 competing products in Osteoporosis